At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 791 enrolled
Drug / intervention
Bevacizumab +3 moredrug
Likely dose
Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
In Brief
A Phase 3 clinical trial evaluating Bevacizumab, Temsirolimus, and 1 other intervention for Renal Cell Carcinoma. Completed, enrolled 791 participants across 172 sites in 30 countries.
Detailed Summary
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesArgentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hong Kong, Hungary, India, Italy, Malaysia, Mexico, Netherlands, Poland, Portugal, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartApr 2008
Primary CompletionApr 2012
Study CompletionApr 2015
TodayJul 2026
First PostedMar 7, 2008
Enrollment StartApr 1, 2008
Primary CompletionApr 1, 2012
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.3 years ago
Interventions
Bevacizumabdrug
Bevacizumab 10 mg/kg intravenous (IV) q8wks
Temsirolimusdrug
Temsirolimus 25 mg IV weekly
Bevacizumabdrug
Bevacizumab 10 mg/kg intravenous (IV) q8wks
Interferon-Alfa 9MUdrug
Interferon-Alfa 9MU SC TIW